TOKYO -- Japan will not be able to receive a stable supply of promising coronavirus therapy remdesivir from its U.S. developer to treat all patients in need, Nikkei learned Friday.
Coronavirus
Japan faces short supply of coronavirus drug remdesivir
Gilead Sciences to distribute enough to cover 140,000 patients worldwide
Some hope Gilead Sciences' Ebola drug remdesivir, left, can prove effective against the novel coronavirus. (Nikkei montage of Reuters/U.S. National Institute of Allergy and Infectious Diseases images)
Read Next
Latest on Coronavirus
